FOLD Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Amicus Therapeutics Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 10.43 USD 4.4%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast FOLD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FOLD is 19.13 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

FOLD Lowest Forecast

Wall Street Target

FOLD Average Forecast

Wall Street Target

FOLD Highest Forecast

Wall Street Target

36% Upside

83% Upside

121% Upside

The latest public price target was made on Dec 19, 2023 by Jeffrey Hung from Morgan Stanley , who expects FOLD stock to rise by 92% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Jeffrey Hung Morgan Stanley	20 USD Upside 92%	4 months ago Dec 19, 2023	Morgan Stanley Upgrades Amicus Therapeutics (FOLD) to Overweight StreetInsider

Price Target	20 USD
Upside/Downside	92%

MannKind Corp

66% Upside

Changchun BCHT Biotechnology Co

62% Upside

Ascletis Pharma Inc

119% Upside

Agios Pharmaceuticals Inc

30% Upside

MannKind Corp

66% Upside

Changchun BCHT Biotechnology Co

62% Upside

Ascletis Pharma Inc

119% Upside

Agios Pharmaceuticals Inc

30% Upside

Kiniksa Pharmaceuticals Ltd

51% Upside

PharmaResearch Co Ltd

37% Upside

Xencor Inc

56% Upside

Bioventix PLC

39% Upside

Revenue
Forecast

The compound annual growth rate of Amicus Therapeutics Inc's revenue for the next 3 years is 34%.

N/A

34%

-2%

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

3%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-14%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for FOLD is 19.13 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

The compound annual growth rate of Amicus Therapeutics Inc's revenue for the next 3 years is 34%.

Join more than 133,400+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.